Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Astrazeneca, Biosyngen, Calliditas, Genexine, Life Molecular, Sumitomo.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Astrazeneca, Biogen, Biosyngen Bridge, Calliditas, F2G, Genexine, Henlius, Highfield, Iksuda, Innocare, OLife Molecular, tsuka, Recce, Samsung Bioepis, SN Bioscience, Sumitomo.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Alphanavi, Anheart, Boehringer Ingelheim, Bristol Myers Squibb, Burning Rock, Immutep, Lianbio, Nippon Kayaku, Shanghai, Sumitomo Pharma.
Fledgling biotechnology company Automera has launched in Singapore with $16 million in series A funding to develop its autophagy-targeting chimera small molecules (AUTACs) platform technology. Automera co-founder and chief technology officer Loong Wang told BioWorld that he and his business partner, Taiyang Zhang, decided to move into the biotechnology space in 2021.
Korean bioventure GI Innovation Inc. inched closer to achieving its goal of “five tech transfer deals in five years” with another licensing deal for its allergy drug, GI-301, with Japan-based Maruho Co. Ltd. for ₩298 billion (US$220.7 million), although share prices still dropped on the news.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Aculys, Akeso, Ascentage, Beigene, Brise, Celltrion, Immunoforge, Immutron, Oncolys, Philogen, Taimed, Takeda,Telix.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Blue Earth Diagnostics, Celltrion Group, Elevar Therapeutics, Fuji Pharma, GSK, Hansoh, Jiangsu Hengrui Pharmaceuticals, Mithra Pharmaceuticals, Sinotau Pharmaceutical.
RSS
